RedHill Biopharma (RDHL) Non Operating Investment Income (2015 - 2019)

RedHill Biopharma (RDHL) has 5 years of Non Operating Investment Income data on file, last reported at -$8000.0 in Q4 2019.

• On a quarterly basis, Non Operating Investment Income rose 99.64% year-over-year to -$8000.0 in Q4 2019; TTM through Dec 2019 was -$344000.0, a 230.77% decrease from a year earlier, with the FY2019 full-year figure at -$344000.0, down 230.77% from the prior year.
• Non Operating Investment Income for Q4 2019 stood at -$8000.0, down from -$5000.0 in the prior quarter.
• Over the last five years, Non Operating Investment Income for RDHL reached as high as $1.7 million in Q3 2017 and fell as low as -$3.9 million in Q4 2017.
• Historically, Non Operating Investment Income has averaged -$408750.0 across 5 years, with a median of -$183500.0 in 2015.
• Across the five-year window, Non Operating Investment Income sank 527.86% in 2017 and surged 2046.0% in 2019, its largest moves.
• Year by year, Non Operating Investment Income stood at -$166000.0 in 2015, then tumbled by 515.66% to -$1.0 million in 2016, then tumbled by 277.59% to -$3.9 million in 2017, then surged by 43.2% to -$2.2 million in 2018, then soared by 99.64% to -$8000.0 in 2019.
• Per Business Quant data, the three most recent Non Operating Investment Income figures were -$8000.0 in Q4 2019, -$5000.0 in Q3 2019, and -$1.3 million in Q2 2019.